OncoMatch/Clinical Trials/NCT07059650
DZD8586 Combination Therapy in Patients With Diffuse Large B-cell Lymphoma (TAI-SHAN12)
Is NCT07059650 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including DZD8586+R-CHOP and DZD8586+R-GemOx for diffuse large b-cell lymphoma.
Treatment: DZD8586+R-CHOP · DZD8586+R-GemOx · DZD8586+BR — This study will treat patients with diffuse large B-cell lymphoma (DLBCL). It will assess the anti-tumor efficacy and safety of DZD8586 combination therapy by using objective response rate and the incidence and severity of adverse events. It will also measure the levels of DZD8586 in the body when combined with immunochemotherapy regimens.
Check if I qualifyExtracted eligibility criteria
Cancer type
Diffuse Large B-Cell Lymphoma
Non-Hodgkin Lymphoma
Biomarker criteria
Excluded: BCL2 rearrangement
Excluded: MYC rearrangement
Disease stage
Required: Stage II, III, IV
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: CD20 monoclonal antibody and anthracycline-containing regimen (R-CHOP) — first-line
adequate first-line treatment containing CD20 monoclonal antibody and anthracyclines (such as R-CHOP-like regimen); relapsed or refractory to first-line R-CHOP-like regimen
Cannot have received: BTK inhibitor
Prior use of BTK inhibitors
Cannot have received: hematopoietic stem cell transplantation
Hematopoietic stem cell transplantation within 90 days prior to first dose
Cannot have received: cell therapy
cell therapy within 90 days prior to first dose
Cannot have received: gene therapy
gene therapy within 90 days prior to first dose
Cannot have received: radiation therapy
Radiation therapy within 14 days prior to first dose
Cannot have received: chemotherapy
Chemotherapy not terminated within 5 half-lives before the first dose
Cannot have received: small-molecule targeted therapy
small-molecule targeted therapy not terminated within 5 half-lives before the first dose
Cannot have received: macromolecule drug therapy (such as antibody therapy)
macromolecule drug therapy (such as antibody therapy) not terminated within 28 days before the first dose
Lab requirements
Blood counts
Adequate bone marrow hematopoietic reserve
Adequate bone marrow hematopoietic reserve and organ function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify